Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
Authors:
Open Access
- 27 September 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1240864
Abstract
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that imposes a major burden on patients and healthcare systems. Three structured literature reviews (treatment guidelines, treatment landscape, and human/clinical/patient burden) and one systematic literature review (economic burden) were conducted to better understand the disease burden and unmet needs for patients with late-stage mCRPC, for whom optimal treatment options are unclear.Methods: Embase®, MEDLINE®, MEDLINE® In-Process, the CENTRAL database (structured and systematic reviews), and the Centre for Reviews and Dissemination database (systematic review only) were searched for English-language records from 2009 to 2021 to identify mCRPC treatment guidelines and studies related to the treatment landscape and the humanistic/economic burden of mCRPC in adult men (aged ≥18 years) of any ethnicity.Results: In total, six records were included for the treatment patterns review, 14 records for humanistic burden, nine records for economic burden, three records (two studies) for efficacy, and eight records for safety. Real-world treatment patterns were broadly aligned with treatment guidelines and provided no optimal treatment sequencing beyond second line other than palliative care. Current post-docetaxel treatments in mCRPC are associated with adverse events that cause relatively high rates of treatment discontinuation or disruption. The humanistic and economic burdens associated with mCRPC are high.Conclusion: The findings highlight a lack of treatment options with novel mechanisms of action and more tolerable safety profiles that satisfy a risk-to-benefit ratio aligned with patient needs and preferences for patients with late-stage mCRPC. Treatment approaches that improve survival and health-related quality of life are needed, ideally while simultaneously reducing costs and healthcare resource utilization.Keywords
This publication has 121 references indexed in Scilit:
- Health-Related Quality of Life in Advanced Prostate Cancer and Its Treatments: Biochemical Failure and Metastatic Disease PopulationsClinical Genitourinary Cancer, 2015
- Epidemiology of Patients with Metastatic Castrate Resistant Prostate Cancer in Europe and AustraliaValue in Health, 2014
- Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European UnionHealth and Quality of Life Outcomes, 2014
- Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care populationCancer Management and Research, 2011
- Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care populationCancer Management and Research, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate CancerValue in Health, 2009
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 StudyJournal of Clinical Oncology, 2008
- Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?Journal of Clinical Oncology, 2003
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996